Results 141 to 150 of about 766,604 (355)

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

T cell recognition of HIV synthetic peptides in a natural infection. [PDF]

open access: bronze, 1989
Rachel Schrier   +8 more
openalex   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

open access: yesHepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger   +7 more
wiley   +1 more source

Susceptibility of human glial cells to infection with human immunodeficiency virus (HIV) [PDF]

open access: bronze, 1987
Stephen Dewhurst   +5 more
openalex   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Trends in drug–drug interaction prevalence and longitudinal associations with health outcomes in the older community‐dwelling population: Findings from The Irish LongituDinal study on Ageing

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims We estimate trends in severe drug–drug interaction (DDI) prevalence and examine longitudinal associations between DDI exposure and health outcomes (emergency department [ED] visits, quality‐of‐life [QoL] and functional decline) over approximately 10‐years in the older community‐dwelling population in Ireland.
John E. Hughes   +2 more
wiley   +1 more source

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Demographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
Natália Bordin Andriguetti   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy